Couldn't agree more that our company have already known about the positive outcomes and most likely will be approved by FDA.
Based on the Research Report by Euroz Hartleys – 8 December 2022 ( Read the full report), Analyst Seth Lizee classified the Company as a ‘Speculative Buy, $0.27 Price Target.
Cheapest NDA Filing on ASX? In our analysis,
* Whilst companies are in varying positions (different disease areas, some with licensing agreements already in place, ex. US approvals, and/or multiple other products)– indicatively, the market has paid ~A$110-600 million on FDA NDA filing day (pre- FDAapproval) and ~A$250-2,500 million upon FDA approval.
*BOT trades well below every single comp listed above with a fully diluted $77 million market cap, which per our analysis would make it one of the cheapest ASX companies seeking FDA approval on their first drug
- Forums
- ASX - By Stock
- BOT
- Ann: Confirmation Sofpironium Bromide NDA Formally Under Review
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-57
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 36.0¢ | $3.051M | 8.277M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 465836 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 301865 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 387357 | 0.370 |
3 | 241000 | 0.365 |
15 | 373586 | 0.360 |
5 | 218767 | 0.355 |
15 | 139007 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 201865 | 2 |
0.380 | 349392 | 5 |
0.385 | 280300 | 3 |
0.390 | 451134 | 6 |
0.395 | 319001 | 3 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |